GeneDx vs Tempus (2026)
Both run their own laboratories and sell into hospitals, for different patients. GeneDx diagnoses rare disease with exome and genome sequencing, interpreted by machine learning and clinical scientists over its dataset of prior cases. Its Multiscore model ranks candidate genes, and placed the diagnostic gene in the top 20 in 93 percent of 9,989 cases (Human Genetics, 2026). In a NICU trial run by the University of Washington and Seattle Children's, rapid genome sequencing gave a precise diagnosis to 49.2 percent of tested infants, against 9.7 percent under conventional care. Tempus is indexed for its software for clinicians, not its laboratory. Next reads record text to find oncology patients who have not received guideline directed care, starting with biomarker testing. Tempus One in EHR is a generative AI assistant inside the record, and nP Notetaker drafts notes from encounter audio. Choose GeneDx for rare disease diagnosis by exome or genome; choose Tempus for oncology software that finds patients missing guideline care.
- You run a NICU, a PICU or a pediatric genetics service.
- You want results returned inside Epic as structured data, as at UNC Health.
- Reanalysis at no extra charge matters to the families you serve.
- Your oncology program misses guideline directed biomarker testing.
- Your physicians want a generative assistant inside the record.
- You want business associate terms published and set out by service.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. GeneDx and Tempus are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | GeneDx | Tempus |
|---|---|---|
| Primary category | Diagnostics & Genomics | Clinical Decision Support |
| Founded | 2000 | Not recorded |
| Headquarters | Gaithersburg, Maryland | Chicago, Illinois |
| Website | genedx.com | tempus.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
GeneDx
-
Product / capability
GeneDx added Report Guide to its Provider Portal, which shows plain language guidance next to eligible exome and genome reports.
Source -
Product / capability
GeneDx introduced Easy Order at the 2026 American Academy of Pediatrics meeting.
Source -
Clinical evidence
GeneDx published results from a study at Seattle Children's supporting hospital wide adoption of rapid genomic sequencing rather than the usual narrow deployment in the NICU or a single specialty service.
Source
Tempus
-
Regulatory / FDA
Tempus said its xR RNA sequencing assay, which detects gene rearrangements and specific splice variants in solid tumor tissue, received certification as a Class C in vitro diagnostic under the EU's IVDR.
Source -
Clinical evidence
Tempus reported an analysis of 60,459 advanced lung cancer cases from 56,969 patients, done with Pfizer, in which an AI panel reading routine H&E slides flagged 12 biomarkers with sensitivity above 80 percent for all of them and above 90 percent for several.
Source -
Regulatory / FDA
Tempus received FDA 510(k) clearance for Tempus ECG-MR, software that reads a standard resting 12 lead ECG and flags signs of moderate or severe mitral regurgitation.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases. Its published Multiscore model, a random forest gene ranker, placed the diagnostic gene in the top 20 in 93 percent of 9,989 cases (Human Genetics, 2026), and it acquired the AI interpretation company Fabric Genomics.
Source: AI Health Index, September 2026
Tempus is a precision medicine company listed on NASDAQ as TEM and based in Chicago, whose core business is molecular laboratory testing. Next reads unstructured record data to find patients who have not received guideline directed care, starting with biomarker testing in oncology, and surfaces them to physicians and precision medicine teams; a prospective study of 662 lung cancer patients in six community health systems, presented at ASCO 2026, reported higher biomarker testing rates.
Source: AI Health Index, September 2026
Questions buyers ask
How do GeneDx and Tempus work with the EHR?
In August 2026 GeneDx added Exome-to-Genome Reflex ordering inside Epic Aura, and the integration page links release notes for Aura updates.
Tempus One in EHR (David) runs inside the electronic health record, with Northwestern Medicine as the deployment Tempus has announced, and Next reads unstructured record data and delivers alerts into clinical workflow. The Next page says workflows are integrated directly into clinical systems and names no record system, standard or marketplace listing. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
How are GeneDx and Tempus priced and sold?
Tests can be billed to the patient's insurance, to an institutional account or to the patient as self-pay; GeneDx accepts commercial insurance, Medicaid, Medicare and Tricare and is in network with many plans, supports prior authorization, and offers financial assistance, sponsored testing programs and interest-free payment plans.
Next, Hub and Tempus One are sold to health systems and practices under enterprise agreements, and the Software Terms of Use set out how each service is licensed without a figure. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
How do GeneDx and Tempus handle patient data?
With GeneDx, the HIPAA notice allows research use when reviewed by an institutional review board or privacy board, and the Multiscore study was run on de-identified data under an IRB waiver of consent.
Retention periods are not stated, and nothing says whether identifiable data from Next or Tempus One reaches a model provider. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
Which settings and specialties do GeneDx and Tempus cover?
For GeneDx, the NICU use is supported by the SeqFirst-neo trial, the pediatric outpatient use by the American Academy of Pediatrics first-tier recommendation, and the online family route opened in August 2026 is limited to children with developmental delay, intellectual disability or epilepsy, subject to clinical appropriateness and state rules.
Next is sold for oncology care gaps, starting with guideline directed biomarker testing, and Tempus also offers cardiology care gap and care pathway solutions; the prospective study behind Next covers early stage lung cancer in six US community health systems. Tempus One in EHR and nP Notetaker are sold to clinicians more broadly. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 30, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records were reviewed on this site in September 2026. Neither publishes a price or a security attestation of its own. Each company runs the laboratory and reports the performance of what it sells. GeneDx's exome and genome tests hold an FDA Breakthrough Device designation and are offered as laboratory developed tests, with no submission described. GeneDx may send collated de identified variant data to third parties for commercial purposes and be paid for it. Its NICU trial reports results for non White infants, but GeneDx publishes no yield or uncertain result rate by ancestry across its own testing. Tempus's Software Terms of Use say the software is intended solely for research use, not for informing patient care, while Next is marketed to find the next step in a patient's care. The same terms provide AI outputs as is and require the customer to review every output. Tempus publishes no missed patient rate for Next, and no results by patient group.
Ask Tempus which governs a clinical deployment of Next, the research use terms or the care marketing, and ask GeneDx for yield and uncertain results by ancestry across its own volume.